Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Clinical trial NCT05594784 · COMPLETED
Trial details
- NCT number
- NCT05594784
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-08
- Primary completion
- 2025-03-25
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.